The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, <i>in vitro</i> and <i>in vivo</i>

Abstract

We have demonstrated that pretreatment with the glutamate-release inhibitor riluzole sensitizes glioma cells to radiation and leads to greater cytotoxicity; these results have clinical implications for patients with glioblastoma.